Other studies confirmed the frequent BRAF mutations in these tumors [335]; interestingly, the dramatic response to BRAF-MEK combination therapy was observed in two cases of metastatic high-grade neuroendocrine carcinoma refractory to standard therapy and displaying BRAF (V600E) mutation [336]. Here, BRAF is linked to neuroendocrine carcinoma.